Biocon disclosed a sharp rise in consolidated net profit for the quarter ended September 2015. During the quarter, the profit of the company rose 3 times to Rs 3.06 billion from Rs 1.02 billion in the same quarter last year.
Revenues for the quarter rose 11.54% to Rs 8.61 billion, compared with Rs 7.73 billion for the prior year period.
The Biopharmaceutical segment grew 4% yoy with sales of Rs 5.78 billion. Within the segment, Biopharma grew 4% delivering Rs 4.59 billion, while branded formulations grew 3% to Rs 1.19 billion.
Syngene, India's only publicly listed research services company has reported a revenue growth of 30% with sales of Rs 2.50 billion.
Operating margin for the quarter stood at 22.94% as compared to 22.40% for the previous year period. Operating Income for the quarter was Rs 1.98 billion, compared with Rs 1.73 billion in the previous year period.
The company has invested Rs 570 million in research and development, up 64% yoy, largely on account of the clinical advancement of several biosimilars and novel programs.
Kiran Mazumdar-Shaw, Chairperson and Managing Director of the company said, 'It has been a landmark quarter for the company with hugely successful listing of Syngene. It has been a stable performance for Biocon this quarter with several growth triggers on the horizon focusing on Biosimilars in emerging markets.'
Earnings per share for the quarter stood at Rs 15.30, registering 2.99 times growth over previous year period.
| Quarterly Results - Consolidated (Rs in mn) |
| As at | Sep - 15 | Sep - 14 | %Change |
| Revenues | 8,618.00 | 7,726.30 | 11.54 |
| Net Profit | 3,059.70 | 1,020.50 | 199.82 |
| Diluted EPS | 15.30 | 5.12 | 198.83 |
Shares of the company gained Rs 5.05, or 1.11%, to trade at Rs 462.00. The total volume of shares traded was 24,028 at the BSE (9.22 a.m., Wednesday).
